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Estimating the fiscal impact of rare diseases
using a public economic framework: a case
study applied to hereditary transthyretin-
mediated (hATTR) amyloidosis
Mark P. Connolly1,2* , Saswat Panda1 , Julien Patris3 and Bouke P. C. Hazenberg4
Abstract
Background: A wide range of rare diseases can have fiscal impacts on government finances that extend beyond
expected healthcare costs. Conditions preventing people from achieving national lifetime work averages will
influence lifetime taxes paid and increase the likelihood of dependence on public income support. Consequently,
interventions that influence projected lifetime work activity, morbidity and mortality can have positive and negative
fiscal consequences for government. The aim of this study was to apply a public economic framework to a rare disease
that takes into consideration a broad range of costs that are relevant to government in relation to transfers
received and taxes paid. As a case study we constructed a simulation model to calculate the fiscal life course
of an individual with hereditary transthyretin-mediated (hATTR) amyloidosis in The Netherlands. In this lethal
disease different progressive disease scenarios occur, including polyneuropathy and/or cardiomyopathy.
Results: Due to progressive disability, health care resource use, and early death, hATTR amyloidosis with polyneuropathy
receives more transfers from government compared to the general population. In a scenario where a patient is diagnoses
with hATTR at age 45, an individual pays €180,812 less in lifetime taxes and receives incrementally €111,695 in transfers
from the government, compared to a person without hATTR. Patients suffering from cardiomyopathy die after median 4
years. The health costs of this scenario are therefore lower than that of the other polyneuropathy-based scenarios.
Conclusions: The fiscal analysis illustrates how health conditions influence not only health costs, but also the cross-sectorial
public economic burden attributed to lost tax revenues and public disability allowances. Due to the progressive nature of
hATTR amyloidosis used in this study, public costs including disability increase as the disease progresses with
reduced lifetime taxes paid. The results indicate that halting disease progression early in the disease course
would generate fiscal benefits beyond health benefits for patients. This analysis highlights the fiscal consequences of
diseases and the need for broader perspectives applied to evaluate health conditions. Conventional cost-effectiveness
framework used by many health technology assessment agencies have well-documented limitations in the field of rare
diseases and fiscal modeling should be a complementary approach to consider.
Keywords: Public economics, Generational accounting, Rare diseases, Fiscal analysis, Hereditary transthyretin-derived
(hATTR) amyloidosis
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Background
The burden of health conditions is often measured from
the healthcare perspective in terms of direct health costs
attributed to a medical condition at specific stages of the
disease and attributed health costs that stop at death or
remission. There is a broader perspective that can be
applied to investments in healthcare interventions using
human capital economics that is seldom considered.
This perspective can reflect the impact of health on the
government finances based on lifetime taxes paid and
demand for public benefits linked to disability status
attributed to health status [1–3]. The government
perspective is particularly relevant in tax finance health
systems where public money is used to pay for health-
care which is the dominant funder in OECD countries
[4]. In contrast with the healthcare perspective, the
government public economic perspective can have con-
sequences even in death as health events and disability
represent unfulfilled lifetime taxes paid, increased social
dependency costs and pension receipts. This perspective
implicates that budget impact analysis could be broad-
ened to include the impact of health and technologies
across all government budgets, not just health, and how
changes in health status will influence other government
budgets [1].
Several frameworks are available for capturing the
financial relationship between citizens and state and the
lifetime transactions that occur. Examples include gener-
ational accounting models, microsimulation models
(STINMOD) and social accounting matrix (SAM) often
used by central governments for evaluating the impact
of policy decisions on current and future generations
[5–9]. Current government promises in the form of
income support, disability support, pensions and health-
care are often included for evaluating cross-sector
impact of policies. Similarly, lifetime tax revenue projec-
tions are included to estimate how population dynamics
and workforce participation will influence government
revenue. Underlying these modeling frameworks are
age-specific cohorts and wage income which determines
government future revenue from direct and indirect
taxes. Variations in population health norms due to
morbidity or early mortality can be used to project the
cross-sectorial impact of health on government. Apply-
ing such a framework makes it possible to evaluate how
changes in public health and investments in healthcare
interventions influence other government budgets be-
yond health [1, 10].
Public economic frameworks applied to health condi-
tions often illustrate the cross-sectorial impact of health
on other government sectors including disability pay-
ments, early retirement, living allowances for maintain-
ing living standards, and lost tax revenues [11]. The
magnitude of the public economic impact is linked to
both the severity of the condition, the age at which
health deteriorates, and the likelihood to remain working
or partially employed.
The aim of this study was to explore the applicability
of applying a broader public economic perspective to
evaluate a rare disease called hereditary transthyretin-
mediated (hATTR) amyloidosis.
hATTR amyloidosis
Amyloidosis is a rare and multiorgan disease that re-
sults in progressive, chronically debilitating morbidity
and increased mortality. hATTR amyloidosis is caused
by a genetic mutation in the transthyretin (TTR) gene
that leads to misfolding of TTR proteins, aggregation
of these TTR proteins into amyloid fibrils, and accu-
mulation of these amyloid fibrils in multiple tissues
and organs throughout the body, affecting the nerves,
the heart, eyes, and the gastrointestinal tract [12–17].
The clinical presentation of hATTR amyloidosis in-
cludes sensory, motor, and autonomic neuropathy as
well as cardiomyopathy. Polyneuropathy manifests as
peripheral neuropathy, autonomic dysfunction, and/or
motor weakness in many cases, making it increasingly
difficult for many patients to perform physical activity
and work [18]. Studies have demonstrated that of the
33.3% patients that are employed, 21.9% report miss-
ing work time due to the disease, and 40.7% report
some impairment at work from the disease [19]. Car-
diomyopathy is also a serious disease manifestation;
in an observational study of 77 patients in The
Netherlands, cardiac involvement was present in half
of the patients presenting with hATTR amyloidosis,
regardless of initial clinical presentation and genotype
[20]. hATTR amyloidosis can lead to significant mor-
bidity and disability, with a median survival of 10–12
years following diagnosis and a strongly reduced
survival of 4 years in those patients presenting with
cardiomyopathy [20–22].
Scoring systems are available for assessing hATTR
amyloidosis disease stage with the polyneuropathy dis-
ability (PND) score being commonly used [13]. Previous
studies reported the relation between PND scores and
the likelihood of work [18]; hence this is a useful rela-
tionship for estimating the fiscal consequences of mor-
bidity from the perspective of government.
In the context of the fiscal model we seek to under-
stand how hATTR amyloidosis morbidity, linked to
employment activity based on PND score, and mor-
tality will influence government costs in The
Netherlands. We believe this framework examines the
broader societal impact of rare diseases, as well as the
potential societal benefits of addressing them. Current
Value Assessment tools typically ignore these benefits,
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and we therefore believe that alternative value assess-
ment framework such as fiscal modelling should be
more routinely used or accepted to inform the
broader value of technologies.
Methods
Model design
A fiscal cost model was developed for estimating pub-
lic economic consequences of hATTR amyloidosis in
the Netherlands. The framework was built based on
similar frameworks used to evaluate investments in
healthcare technologies and to estimate disease bur-
den [3, 23]. The calculator estimates the difference
between the average population adjusted for age-
specific mortality and disability and simulated individ-
ual scenarios of hATTR amyloidosis patient journeys
in order to estimate the incremental public economic
impact. The analysis estimates lifetime direct and in-
direct taxes paid in both cohorts and the incremental
benefits received in terms of disability payments, old-
age pensions, and healthcare resource use costs.
Taxes consist of direct taxes on earnings, and indirect
taxes which are calculated by using a flat VAT tax
rate on taxable disposable income.
The analysis first required constructing the average
fiscal life course for the general population adjusted for
age-specific mortality. We apply age-specific income
adjusted for labor force participation rate to derive direct
taxes paid to government [24, 25]. Standard published
direct tax rates for the Netherlands were applied to age-
specific income data [26]. We then applied disposable
income to estimate the age-specific indirect taxes paid to
VAT through consumption (the VAT tax rate used was
21%) [27, 28].
Similarly, we apply rate of retirement to the general
population to indicate transition from employment to
pension which changes the annual income and taxes
paid. The retirement age, productivity growth,
discount rate for costs, and cost-inflation rate are set
to 65, 1, 4, and 1.5% for our analysis. Productivity
growth was estimated to be 1% by calculating the
geometric mean of productivity growth between 1990
to 2017 for the Netherlands [29]. Cost inflation was
estimated to be 1.5% by figuring the geometric mean
of past inflation trends in the Netherlands from 2001
to 2018 [30]. We used a retirement age of 65 based
on the current Dutch policy on retirement [31]. We
use a 4% discount rate per Dutch Health Economic
Guidelines [32].
Health care costs
Healthcare costs by PND score were derived from a
resource use survey in the Netherlands and applying
local unit costs to each item. The health cost survey
was based on best supportive care excluding liver
transplantation and TTR tetramer-stabilizing treat-
ment in which we applied estimated resource use pat-
terns by PND score to known cost tariffs. The
healthcare costs for those in the non-hATTR amyl-
oidosis population were derived from the PAID (Prac-
tical Application to Include future Disease costs)
calculator, version 1.1, a tool to estimate per capita
indirect medical costs for the Netherlands [33]. The
diseases which resemble symptoms of hATTR amyl-
oidosis were deselected, and the results of the calcula-
tor were used for determining per capita health care
expenditure in the non-hATTR amyloidosis popula-
tion [34]. The output from the health cost analysis
are provided in Table 1, and health resource unit
costs are provided in the Additional file 1.
Economic inputs
Age-specific earnings, labor force participation, un-
employment, old age pension, and disability pension
figures were obtained from the Statistics Netherlands’
data portal [35].
Disability payments
Disability payments in the Netherlands are linked to
disability level determined by medical experts with fixed
percentages of disability payments available based on
earnings and projected wage losses. To account for
hATTR amyloidosis disability, we map disability scores
to different percentage disability defined by Dutch law
[36].
Table 1 Health care resource use hATTR amyloidosis best



















aN-terminal pro b-type natriuretic peptide; b: Healthcare resource use,
polyneuropathy; c: Healthcare resource use, severe cardiomyopathy
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Patient scenarios
In hATTR amyloidosis, disease progression and mortal-
ity vary widely, in particular when cardiac involvement is
present [18]. Variation in disease progression and mor-
tality are largely dependent on the type of mutation of a
particular patient. Consequently, it is difficult to model
disease progression that reflects a typical cohort. To
overcome this challenge, we have defined typical scenar-
ios from published studies [18, 37, 38].
We assume that after someone has been diagnosed
with hATTR amyloidosis, they will have some form
of polyneuropathy disability (PND) over time, which
worsens until death from PND, other co-morbidities,
or other causes. We assume that there are no back
transitions from more severe PND stages to less se-
vere PND stages. We assume PND progression is
non-reversible.
We opted to use a scenario-based approach to derive
results, as patients will have different experiences with
hATTR amyloidosis. As such, we developed scenarios
for how long a patient may stay in each PND score
based on real world evidence on ranges of time for dis-
ease duration, presented in the published literature [37,
38]. The median value for disease duration was used to
develop a scenario where a patient might have a “median
progression” through disease states—transitioning to se-
vere disease as expected. The maximum value for disease
duration was used to present the extreme case where a
patient may live with hATTR amyloidosis for the max-
imum observed time. We also designed scenarios to
have an early disease onset and late disease onset, where
the patient is diagnosed at age 45 (scenarios 1 and 2)
and age 60 (scenarios 3 and 4), respectively. These values
were used as they are plausible ages where many pa-
tients are diagnosed in the literature [20, 37, 38]. Finally,
we designed a scenario to highlight the impact of cardio-
myopathy as main manifestation of hATTR amyloidosis.
This scenario is meant to emphasize the severity of
having cardiomyopathy in a patient with hATTR amyl-
oidosis. This scenario accounts for the fact that the
median survival of severe cardiomyopathy is about 4
years, after which the patient dies as a result of compli-
cations caused by cardiomyopathy, rather than through
progression to the last stage of polyneuropathy [39]. The
scenarios were also evaluated with a local expert to
ensure that these are plausible disease profiles of pa-
tients (Table 2).
Results
We estimate that in the general population between the
timeframe of ages 40 and 80, a person receives €338,330,
and pays €319,922 in taxes (Table 3). Scenarios 1–3
illustrate hypothetical cases where a patient has hATTR
amyloidosis without severe cardiomyopathy. In Scenario
1 (Fig. 1), where a patient has an early disease onset with
a median disease progression, resulting in early death at
age 55—their lifetime earnings are diminished, and life-
time taxes are diminished. In scenario 1, the person
would pay €180,812 less in taxes. Conversely, transfers
are far greater than that of the general population, in
this scenario, where a person receives €111,695 more in
pensions, disability payments, and healthcare from the
government. Although Scenario 2 (Fig. 2) is a case where
the patient lives ten additional years with the disease,
their earning potential is only somewhat greater than
Scenario 1, as much of the later years of life are years
lived in disability. The lifetime earnings of a person in
Scenario 2 are €348,952, while the earnings of a person
in Scenario 1 are €247,559. Scenario 3 (Fig. 3) shows the
profile of a person with a late disease onset and median
disease progression, and this scenario accounts for the
impact of receiving old age pensions from the govern-
ment for the time alive after retirement.
Scenario 4 estimates the fiscal course of an individual
with hATTR amyloidosis with severe cardiomyopathy,
where this main manifestation causes the patient to
succumb due to early mortality within only 4 years,
before reaching the latest stage of polyneuropathy. The
health costs in this scenario are less significant than that
of the other three scenarios (Fig. 4). This scenario esti-
mates a reduction in lifetime taxes paid of €13,156 over
a person in the general population.
Discussion
All health conditions have the capacity to influence
public economics beyond health service costs [1, 7].
The fiscal analysis described here illustrates how
hATTR amyloidosis influences not only health costs,
but also the cross-sectorial public economic burden
attributed to lost tax revenues and public disability al-
lowances to maintain living standards for people un-
able to work. Due to progressive disability, health




Early disease onset, at age 45 at PND state 1, with a median
progression through PND states, and death at age 55 at PND
state 4, without severe cardiomyopathy.
Scenario
2
Early disease onset, at age 45 at PND state 1, with a slow
progression through PND states, and death at age 65 at PND
state 4, without severe cardiomyopathy.
Scenario
3
Late disease onset, at age 60 at PND state 1, with a median
progression through PND states, and death at age 70 at PND
state 4, without severe cardiomyopathy.
Scenario
4
Late disease onset and late diagnosis, at age 60 during PND
state 2, in a patient with severe cardiomyopathy, where the
patient dies within 4 years, at PND state 3b, before reaching
PND state 4.
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care resource use, and early death, patients with
hATTR amyloidosis with polyneuropathy receive more
transfers from government compared to the general
population. Disability and succumbing to early death
decrease the labor force participation of a patient
with hATTR amyloidosis, and thus their lifetime tax
contribution compared to a person without hATTR
amyloidosis in the general population from ages 40 to
80. When patients suffer from severe cardiomyopathy
as part of hATTR amyloidosis, this main manifest-
ation causes the patient to succumb to early mortality
within only 4 years, far before reaching the latest
Table 3 The estimated per person economic impact between the ages 40–80 attributed to patients with hATTR amyloidosis in





















€ 2150 € 180,949 (€ 178,
799)
€ 285,355 (€ 283,
204)
€ 84,011 (€ 81,861) € 55,369 (€ 53,219)
Pensions € 130,082 € 0 € 130,082 € 0 € 130,082 € 55,527 € 74,556 € 0 € 130,082
Health costs € 206,098 € 269,076 (€ 62,979) € 656,129 (€ 450,
031)
€ 322,218 (€ 116,
120)
€ 110,502 € 95,596
Total transfers € 338,330 € 450,025 (€ 111,
695)
€ 941,483 (€ 603,
153)
€ 461,756 (€ 123,
426)




€ 577,114 € 247,559 € 329,555 € 348,952 € 228,162 € 561,244 € 15,870 € 549,494 € 27,620
Taxation
Direct tax € 229,148 € 100,172 € 128,976 € 140,898 € 88,250 € 224,631 € 4517 € 220,336 € 8812
Indirect tax € 90,774 € 38,939 € 51,836 € 54,887 € 35,888 € 88,278 € 2496 € 86,430 € 4344




36.67 15.12 21.55 24.44 12.23 28.81 7.87 24.44 12.23
Productive life
years lived
20.15 6.60 13.55 9.77 10.39 17.89 2.26 17.34 2.82
Fig. 1 Lifetime transfers and taxes for Scenario 1 Fig. 2 Lifetime transfers and taxes for Scenario 2
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stage of polyneuropathy, as such the health costs are
less significant than that of the other three scenarios
and even lower than expected in the general popula-
tion. Due to the progressive nature of hATTR amyl-
oidosis used in our case study, public costs including
disability increase as the disease progresses with
reduced lifetime tax contributions. The results indi-
cate that halting disease progression early in the
course of the disease would generate fiscal benefits
beyond health benefits for patients. On the other
hand, only slowing down the course of the disease
would even strongly increase the total transfer costs
as reflected in scenario 2 compared to scenario 1.
The results described here in all scenarios illustrate
how early mortality from hATTR amyloidosis can
lead to pension cost savings for government. How-
ever, considering the costs of social protection that
are paid to people with hATTR amyloidosis there is
no overall saving to the public system. This study il-
lustrates the cross-sectorial impact of health
conditions that create dependency on social programs
due to the inability to work. The results described
here are likely an underestimate of the fiscal losses as
many people with hATTR amyloidosis will rely heav-
ily on a close relative that may have to quit their job
or have to reduce work activity which further trans-
lates to reduced tax revenues for government.
In recent years with the widespread application of
cost-effectiveness analysis to inform allocation deci-
sions in healthcare, many have questioned whether
this methodological approach is appropriate for rare
diseases and orphan drugs [40, 41]. As previously
mentioned here, all health conditions can have fiscal
consequences, however there are some features of
rare diseases which could result in greater fiscal im-
pact compared to adult onset chronic conditions. For
instance, many rare diseases impact from birth, are
severely disabling and can greatly reduce life-
expectancy [40], all features that can give rise to fiscal
consequences in comparison to other chronic health
conditions that often start later in life. With this in
mind many, have noted the need to consider all
elements of value and to ensure the full value of or-
phan drugs is reflected to paying audiences [40, 42].
In the framework described here, we reflect the gov-
ernment perspective which captures the fiscal transac-
tions between citizens and state – none of which are
captured by the existing cost-effectiveness perspectives
of health service and societal. The government per-
spective is a meso-level perspective between health
and society.
Unlike health costs, public costs are often defined
by statutory disability payment rates, and various pub-
lic allowances, therefore they are capped and are the
same regardless of the underlying disease. Access to
these benefits is defined by disability status and the
age at which they are accessed. For example, a person
claiming disability due to heart disease or any other
condition would be entitled to the same public bene-
fits as a person with hATTR amyloidosis as long as
the disability level was deemed to be equivalent.
Therefore, the fiscal results described here are applic-
able to other medical conditions that have a compar-
able impact on lifetime productivity as shown here
for hATTR amyloidosis. Furthermore, as described
here, governments lose money from health conditions
based on earning capacity and ability to pay taxes.
Fig. 4 Lifetime transfers and taxes for Scenario 4
Fig. 3 Lifetime transfers and taxes for Scenario 3
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Similar estimates could be derived for other rare dis-
eases applying this approach.
The main public economic variation between condi-
tions is the age of disease onset and rate of progres-
sion which causes someone to become disabled.
Diseases that impact early life can mean lower life-
time earnings, lower savings and lower wealth accu-
mulation which can influence living standards in
retirement. This would suggest that the ability to pre-
vent health events or halt disease progression early in
the disease course may enable people to remain pro-
ductive: this will have benefits on earnings and wealth
accumulation, as well as reducing demand for public
benefits now and in the future. However, this does
highlight one of the weaknesses of fiscal modeling
that would tend to favor treating younger cohorts.
Whilst this does pose equitable challenges, this is a
fiscal reality and highlights the interdependence
between generations in terms of taxes paid and bene-
fits received. Despite these limitations, we believe this
analysis highlights the need for a broader perspective
when applied to health as the conventional cost-
effectiveness framework used by many health technol-
ogy assessment (HTA) agencies typically does not ac-
count for other costs beyond direct healthcare costs.
Excluding health related costs, the broader fiscal
consequences of health conditions are consistent
across diseases. Governments pay statutory amounts
for disability regardless of the underlying health con-
dition. Hence, the results shown here are representa-
tive of what any individual might receive who is
disabled for any health condition such as cardiovascu-
lar disease, arthritis, renal failure or hATTR. In this
regard the non-health related fiscal impacts described
here are directly transferable to other health condi-
tions in the Netherlands based on age-specific statis-
tical averages. The variation in fiscal costs that is
observed across rare diseases is mostly attributable to
direct health costs. Furthermore, from our experience
we observe consistency across many Western
European democracies. Hence, we would expect a
similar pattern of social spending and reductions in
lifetime tax contributions to exist in other European
markets [43].
Healthcare in the Netherlands is financed through a
statutory health insurance scheme with regulated
competition, with prevention and social insurance fi-
nanced through taxation. The government is respon-
sible for setting priorities and monitoring costs and
quality through a range of agencies [44]. New phar-
maceuticals are evaluated by the Zorginstituut Neder-
land in which a societal perspective is applied with
emphasis on health costs. In contrast, the fiscal mod-
eling approach described here is between the health
sector and societal perspective reflecting specific fi-
nancial transactions between citizen and state. The
added value of the fiscal approach i.e. “government
perspective”, is that tax revenue losses and gains can
be accounted for based on investments in healthcare.
In this regard, fiscal modeling helps to illustrate that
health and healthcare are not only a cost, but also an
investment, that can influence public accounts based
on health spending.
Fiscal models in health can inform a range of gov-
ernment stakeholders in relation to how changes in
morbidity and mortality influence public accounts. In
the case of hATTR amyloidosis, the public economic
burden is relatively small due to low prevalence, how-
ever applying a broader public health burden on this
type of analysis can be more informative. For ex-
ample, previous studies have explored the fiscal con-
sequences of diabetes and obesity which can be in the
billions of dollars [11]. A cross-sectorial public eco-
nomic analysis as described here can inform a range
of different government sectors regarding future cost
and revenue implications.
Introducing fiscal models in healthcare decision
making can introduce new factors to consider in re-
source allocation decisions. Firstly, the assessment in-
dicates there are many more public costs than simply
looking at the health costs. This is an important con-
sideration as health systems in developed countries
are mostly tax financed in the same manner as other
pay-as-you-go public programs. Therefore, health in-
vestments that delay progression or prevent events
from occurring offer fiscal benefits for government in
terms of future taxes and delaying disability payments.
Secondly, considering that many public sector costs
attributed to rare diseases are often non-health re-
lated, we must gauge how these additional public cost
elements should be considered in relation to pricing
of new interventions that slow down progression and/
or prevent morbidity and mortality. Perhaps most
challenging is how to rationalize the observation that
early mortality can save costs for government. There
are no clear answers for this, however from our own
work we have observed situations where conclusions
from fiscal models can conflict those from cost-
effectiveness models [45].
Conclusions
The public economic framework described here can be
an added approach for estimating disease burden and
therapeutic interventions for rare diseases. We believe
this approach can be applied to a range of different rare
diseases and offers a complementary approach to cost-
effectiveness analysis and can be used for priority
setting.
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Appendix
Table 4 Table of volume of resources used per disease state in hATTR amyloidosis to derive. Cost per 6-month cycle by health state
in 2018 € (*)
Patisiran Drug Admin Other HCRU PN HCRU CM AEs Total cost
NT proBNP< 3000 pg/mL PND 0 178,819 4480 38 47 3063 151 186,597
PND I 178,819 4480 38 874 3063 151 187,423
PND II 178,819 4480 38 1349 3063 151 187,898
PND IIIA 178,819 4480 38 2455 3063 151 189,004
PND IIIB 178,819 4480 38 3514 3063 151 190,063
PND IV 178,819 4480 38 35,839 3063 151 222,388
NT proBNP≥3000 pg/mL PND 0 178,819 4480 38 47 4330 151 187,864
PND I 178,819 4480 38 874 4330 151 188,691
PND II 178,819 4480 38 1349 4330 151 189,166
PND IIIA 178,819 4480 38 2455 4330 151 190,272
PND IIIB 178,819 4480 38 3514 4330 151 191,331
PND IV 178,819 4480 38 35,839 4330 151 223,656
Tafamidis Drug Admin Other HCRU PN HCRU CM AEs Total cost
NT proBNP< 3000 pg/mL PND 0 70,468 – – 110 9188 584 80,350
PND I 70,468 – – 2039 9188 584 82,278
PND II – – – 3147 9188 355 12,690
PND IIIA – – – 5727 9188 355 15,270
PND IIIB – – – 8198 9188 355 17,741
PND IV – – – 83,624 9188 355 93,166
NT proBNP≥3000 pg/mL PND 0 70,468 – – 110 12,991 584 84,153
PND I 70,468 – – 2039 12,991 584 86,081
PND II – – – 3147 12,991 355 16,493
PND IIIA – – – 5727 12,991 355 19,073
PND IIIB – – – 8198 12,991 355 21,544
PND IV – – – 83,624 12,991 355 96,970
BSC Drug Admin Other HCRU PN HCRU CM AEs Total cost
NT proBNP< 3000 pg/mL PND 0 – – – 110 9188 355 9653
PND I – – – 2039 9188 355 11,581
PND II – – – 3147 9188 355 12,690
PND IIIA – – – 5727 9188 355 15,270
PND IIIB – – – 8198 9188 355 17,741
PND IV – – – 83,624 9188 355 93,166
NT proBNP≥3000 pg/mL PND 0 – – – 110 12,991 355 13,457
PND I – – – 2039 12,991 355 15,385
PND II – – – 3147 12,991 355 16,493
PND IIIA – – – 5727 12,991 355 19,073
PND IIIB – – – 8198 12,991 355 21,544
PND IV – – – 83,624 12,991 355 96,970
(*) In this calculation the following costs are not considered: Health care resource use one off costs, end of life care, and orthotic liver transplant; additionally,
discontinuation of Patisiran is not included in these costs
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13023-019-1199-x.
Additional file 1: Table S1. Cost data for hATTR by PND stage in Euros
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